Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
M.D Bin Cao, M.D Yeming Wang, M.D Hongzhou Lu, M.D Chaolin Huang, M.D Yumei Yang, Ph.D Lianhan Shang, M.D Zhu Chen, M.D Rongmeng Jiang, M.D Yihe Liu, M.D Ling Lin, M.D Ping Peng, M.D Fuxiang Wang, M.D Fengyun Gong, M.D Honglin Hu, M.S Cong Cheng, M.D Xiangyang Yao, M.D Xianwei Ye, M.D Hourong Zhou, M.D Yinzhong Shen, M.D Chenfan Liu, M.D Chunying Wang, M.D Zhennan Yi, M.D Bijie Hu, M.D Jiuyang Xu, M.D Xiaoying Gu, Ph.D Jingshan Shen, Ph.D Yechun Xu, Ph.D Leike Zhang, Ph.D Jia Fan, M.D Renhong Tang, Ph.D Chen Wang
New England Journal of Medicine, doi:10.1056/nejmoa2301425
BACKGROUND Simnotrelvir is an oral 3-chymotrypsin-like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a phase 1B trial.
CONCLUSIONS Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns.
Appendix
References
Akhmerov, Marbán, COVID-19 and the heart, Circ Res
Arbel, Sagy, Hoshen, Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge, N Engl J Med
Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an openlabel, platform-adaptive randomised controlled trial, Lancet
Cao, Gao, Bao, VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19, N Engl J Med
Cao, Jian, Wang, Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution, Nature
Garcia-Beltran, Lam, Denis, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell
Huang, Li, Gu, Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study, Lancet Respir Med
Islam, Riaz, Efa, Farjana, Mahmood, Health-related quality of life of the adult COVID-19 patients following one-month illness experience since diagnosis: findings of a cross-sectional study in Bangladesh, PLoS One
Jiang, Su, Shang, Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir, Nat Commun
Mukae, Yotsuyanagi, Ohmagari, A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part, Antimicrob Agents Chemother
O'brien, Fleming, A multiple testing procedure for clinical trials, Biometrics
Pfizer, Analyst and investor call to discuss the first COVID-19 comprehensive approach: Pfizer-BioNTech vaccine and Pfizer's novel oral antiviral treatment candidate
Wang, Tang, Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial, Lancet Reg Health West Pac
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet
Yang, Yang, Yao, A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects, Eur J Pharm Sci
